BC Innovations | Aug 14, 2019
Distillery Therapeutics

Antihelminthic compound bithionol could treat MRSA infection

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus The antihelminthic bithionol could be repurposed to treat methicillin-resistant S. aureus (MRSA) infections. In bacterial growth assays, bithionol reduced growth of three MRSA strains and a vancomycin-resistant S. aureus...
BC Innovations | Nov 9, 2016
Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Mouse studies suggest an ENPP2 inhibitor could help treat liver fibrosis in NASH. In an in vitro assay, a previously identified fluoroindoylthiofluorobenzoic acid analog (PAT-505) inhibited ENPP2 activity with an IC 50...
BC Week In Review | Apr 11, 2011
Company News

Champions Oncology, BC Cancer Agency deal

Champions Oncology (formerly Champions Biotechnology Inc. ) exercised its 2010 option for exclusive, worldwide rights to develop and commercialize the agency's cancer candidate Irinophore C. The liposomal formulation of irinotecan is expected to start Phase I...
BC Week In Review | Nov 23, 2009
Company News

Champions Biotechnology, Southern Research Institute, Yale University deal

The institute and Yale granted Champions exclusive, worldwide rights to develop and commercialize bithionol to treat cancer. Champions plans to evaluate the efficacy of the small molecule autotaxin ( ENPP2 , ATX) inhibitor alone or in combination...
Items per page:
1 - 4 of 4